• Ticker:- PPH;false;MVPPH;
  • Ticker Group:- ETFEQ_IND;false;;
  • How to Purchase

Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

Pharmaceutical ETF PPH

  • Full Name: Market Vectors®
    Pharmaceutical ETF (PPH)

    Management Style: Replication

    Underlying Index: Market Vectors US Listed Pharmaceutical 25 Index (MVPPHTR)

    Index Provider: Market Vectors Index Solutions

    Index Description: MVPPHTR is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies.

  •  
      

    • Fund Ticker

      PPH
    • Exchange

      NYSE Arca
    • Commencement

      12/20/2011
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      MVPPHTR
    • Index Rebalancing

      Quarterly
  •  
    as of 12/17/14

    • 30-Day SEC Yield1

      1.90%
    • Total Net Assets

      $343.2M
    • Number of Holdings

      26
    • Options

      Available
    • Gross Expense Ratio2

      0.43%
    • Net Expense Ratio/TER2

      0.35%
    • Distribution Frequency

      Quarterly
    • Next Distribution Date

      12/26/2014
  • Key Points

    Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
    Industry Leaders
    Index methodology favors the largest companies in the industry
    Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
     
  • Trading Information

    • Fund Ticker

      PPH
    • Index Total Return Ticker

      MVPPHTR
    • NAV

      PPHNV
    • Intraday NAV (IIV)4

      PPHIV
    • Shares Outstanding

      5,338,138
    • Estimated Cash

      PPHEU
    • Total Cash

      PPHTC
    • CUSIP

      57060U217
    • ISIN

      US57060U2179
    Source: Bloomberg
  • Fees & Expenses2

    • Management Fee

      0.35%
    • Other Expenses

      0.08%
    • Gross Expense Ratio

      0.43%
    • Fee Waivers and
      Expense Reimbursement

      -0.08%
    • Net Expense Ratio/TER2

      0.35%
    2 Expenses for PPH are capped contractually at 0.35% until at least 2/01/15. TER, or Total Expense Ratio, is also referred to as "Net Expense Ratio". Cap excludes certain expenses, such as interest.
  • Prices as of 12/17/14

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    PPH $64.29
    $64.27
    70,937
    95,411
    $0.95 / +1.50%
    $0.92 / +1.45%
    +22.0%
    +22.1%
    $-0.02
    -0.03%
  • View All Indices » View All ETFs » Performance History: Average Annual Total Returns* (%)

    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) 4.48 6.87 26.92 29.60 -- -- -- 26.00
    PPH (Share Price) 4.50 6.85 26.92 29.36 -- -- -- 26.38
    MVPPHTR (Index) 4.46 6.86 26.36 29.45 26.61 -- -- 25.88
    Performance Differential (NAV - Index) 0.02 0.01 0.56 0.15 -- -- -- 0.12
    1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR LIFE
    12/20/11
    PPH (NAV) 2.10 2.89 21.27 35.19 -- -- -- 25.69
    PPH (Share Price) 2.24 2.89 21.44 35.39 -- -- -- 26.15
    MVPPHTR (Index) 2.12 2.88 20.76 35.09 27.11 -- -- 25.57
    Performance Differential (NAV - Index) -0.02 0.01 0.51 0.10 -- -- -- 0.12
  • View All Holdings »Top 10 Holdings (%)as of 11/30/14

    Total Holdings: 26
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Johnson & Johnson
    JNJ US
    358,434
    38,800,48010.76
    Novartis Ag
    NVS US
    367,119
    35,482,0529.84
    Pfizer Inc
    PFE US
    851,143
    26,513,1047.35
    Merck & Co Inc
    MRK US
    337,777
    20,401,7305.66
    Abbvie Inc
    ABBV US
    269,362
    18,639,8505.17
    Bristol-Myers Squibb Co
    BMY US
    301,583
    17,808,4764.94
    Actavis Plc
    ACT US
    65,178
    17,637,8184.89
    Novo Nordisk A/S
    NVO US
    372,502
    16,933,9404.70
    Glaxosmithkline Plc
    GSK US
    362,023
    16,815,9684.66
    Allergan Inc/United States
    AGN US
    77,654
    16,609,4144.61
    Top 10 Total (%)62.58
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 11/30/14

    • Country

      % of Net Assets
    • U.S.

      61.9
    • SWITZERLAND

      9.8
    • UNITED KINGDOM

      8.9
    • DENMARK

      4.7
    • FRANCE

      4.6
    • ISRAEL

      3.7
    • CANADA

      3.3
    • IRELAND

      3.1
    • Other

      -0.1
  • Sector Weightings (%) as of 11/30/14

    • Sector

      % of Net Assets
    • Health Care

      100.1
    • Other

      -0.1